Malignant neoplasm of bladder
Chapter 2:Neoplasms
ICD-10 C67 is a billable code used to indicate a diagnosis of malignant neoplasm of bladder.
Malignant neoplasm of the bladder, classified under ICD-10 code C67, refers to cancerous tumors that develop in the bladder's epithelial lining. This condition is characterized by uncontrolled cell growth, leading to the formation of tumors that can invade surrounding tissues and metastasize to other parts of the body. The bladder is a hollow organ that stores urine, and its malignancies can present with symptoms such as hematuria (blood in urine), dysuria (painful urination), and increased urinary frequency. Risk factors include smoking, exposure to certain chemicals, chronic bladder inflammation, and a history of urinary tract infections. Staging of bladder cancer is crucial for determining treatment options and prognosis, typically classified using the TNM system, which assesses tumor size (T), lymph node involvement (N), and metastasis (M). Surgical management may involve transurethral resection of the bladder tumor (TURBT), radical cystectomy, or bladder-preserving therapies, depending on the stage and grade of the cancer. Accurate coding is essential for appropriate treatment planning and reimbursement.
Detailed pathology reports, imaging studies, and surgical notes.
Diagnosis and management of bladder tumors, post-operative follow-up, and surveillance for recurrence.
Ensure accurate staging and grading of tumors to guide treatment decisions.
Comprehensive treatment plans, chemotherapy regimens, and response assessments.
Management of advanced bladder cancer, coordination of multi-disciplinary care, and palliative care considerations.
Documenting the rationale for treatment choices and monitoring for side effects.
Used for diagnosis and staging of bladder cancer.
Cystoscopy report detailing findings and biopsy results.
Urologists must document the extent of the procedure and any findings.
Performed for muscle-invasive bladder cancer.
Operative report detailing the surgical approach and findings.
Oncologists must ensure accurate staging and post-operative care documentation.
The primary treatment for muscle-invasive bladder cancer is radical cystectomy, often combined with chemotherapy or radiation therapy depending on the individual case.
Bladder cancer is staged using the TNM system, which assesses tumor size (T), lymph node involvement (N), and metastasis (M).
